{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:12:24Z","timestamp":1790100744121,"version":"4.0.1"},"reference-count":100,"publisher":"Bioscientifica","issue":"5","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Somatic mutations in the telomerase reverse transcriptase (TERT) promoter are key molecular events in thyroid carcinogenesis and are strongly associated with aggressive clinical behaviour. The c.-124C&amp;gt;T and c.-146C&amp;gt;T hotspot mutations, discovered in 2013, are now recognised as major mechanisms of TERT reactivation and as independent predictors of disease-specific survival, recurrence, and disease refractoriness to radioiodine. TERT can also be reactivated by multiple regulatory layers converging on telomerase upregulation. Beyond telomere maintenance, TERT enhances ribosome biogenesis, cooperates with BRAFV600E-driven transcriptional programmes, and modulates NF-\u03baB-associated inflammatory and stress responses, thereby promoting dedifferentiation and therapy resistance. Clinically, TERT promoter mutations, particularly when co-occurring with BRAFV600E, increase in prevalence from papillary to anaplastic thyroid carcinoma and are associated with an increased risk of radioiodine-refractory disease, supporting their use in risk stratification. However, isolated TERT promoter mutations are more often associated with intermediate risk tumours and comparatively better outcomes, underscoring the importance of molecular context. The recent approval of the telomerase inhibitor imetelstat and the preclinical success of the rRNA transcription inhibitor CX5461 in restoring differentiation and iodine uptake support telomerase- and ribosome-targeted strategies as emerging therapeutic avenues for TERT-driven thyroid cancers.<\/jats:p>","DOI":"10.1530\/etj-26-0068","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:46:55Z","timestamp":1788972415000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":0,"title":["TERT reactivation in thyroid cancer: mechanisms, clinical implications, and therapeutic opportunities"],"prefix":"10.1530","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1190-1437","authenticated-orcid":true,"given":"Linh T T","family":"Nguyen","sequence":"first","affiliation":[{"name":"Kolling Institute, Northern Sydney Local Health District and Sydney Medical School, Faculty of Medicine and Health, University of Sydney 1 , , ,","place":["Sydney, New South Wales, Australia"]},{"name":"The 108 Military Central Hospital 2 , ,","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Glover","sequence":"additional","affiliation":[{"name":"Kolling Institute, Northern Sydney Local Health District and Sydney Medical School, Faculty of Medicine and Health, University of Sydney 1 , , ,","place":["Sydney, New South Wales, Australia"]},{"name":"The Kinghorn Cancer Centre, Garvan Institute of Medical Research, St. Vincent\u2019s Clinical School, Faculty of Medicine, University of New South Wales 3 , , ,","place":["Darlinghurst, New South Wales, Australia"]},{"name":"Specialty of Surgery, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney 4 , , ,","place":["Camperdown, New South Wales, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Gild","sequence":"additional","affiliation":[{"name":"Kolling Institute, Northern Sydney Local Health District and Sydney Medical School, Faculty of Medicine and Health, University of Sydney 1 , , ,","place":["Sydney, New South Wales, Australia"]},{"name":"Department of Endocrinology, Royal North Shore Hospital, Northern Sydney Local Health District 5 , , ,","place":["Sydney, New South Wales, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-5509","authenticated-orcid":true,"given":"Martyn","family":"Bullock","sequence":"additional","affiliation":[{"name":"Kolling Institute, Northern Sydney Local Health District and Sydney Medical School, Faculty of Medicine and Health, University of Sydney 1 , , ,","place":["Sydney, New South Wales, Australia"]},{"name":"Department of Endocrinology, Royal North Shore Hospital, Northern Sydney Local Health District 5 , , ,","place":["Sydney, New South Wales, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"2026092213562619000_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2026092213562619000_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"2026092213562619000_bib3","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092213562619000_bib4","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"2026092213562619000_bib5","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"2026092213562619000_bib6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2026092213562619000_bib7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41576-019-0099-1","article-title":"Telomeres and telomerase: three decades of progress","volume":"20","author":"Shay","year":"2019","journal-title":"Nat Rev Genet"},{"key":"2026092213562619000_bib8","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/ERC-15-0533","article-title":"TERT promoter mutations in thyroid cancer","volume":"23","author":"Liu","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"2026092213562619000_bib9","doi-asserted-by":"crossref","first-page":"E1130","DOI":"10.1210\/jc.2013-4048","article-title":"TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer","volume":"99","author":"Liu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092213562619000_bib10","doi-asserted-by":"crossref","first-page":"E1562","DOI":"10.1210\/jc.2013-2383","article-title":"Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease","volume":"98","author":"Landa","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092213562619000_bib11","doi-asserted-by":"crossref","first-page":"E754","DOI":"10.1210\/jc.2013-3734","article-title":"TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas","volume":"99","author":"Melo","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092213562619000_bib12","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the Most aggressive papillary thyroid cancer with highest recurrence","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026092213562619000_bib13","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/cncr.29934","article-title":"Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients","volume":"122","author":"Song","year":"2016","journal-title":"Cancer"},{"key":"2026092213562619000_bib14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamaoncol.2016.3288","article-title":"Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer","volume":"3","author":"Liu","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026092213562619000_bib15","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1210\/clinem\/dgae327","article-title":"Coexisting RET\/PTC and TERT promoter mutation predict poor prognosis but effective RET and MEK targeting in thyroid cancer","volume":"109","author":"Zhang","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092213562619000_bib16","doi-asserted-by":"crossref","first-page":"8693","DOI":"10.1093\/nar\/gkw549","article-title":"hTERT promotes tumor angiogenesis by activating VEGF via interactions with the Sp1 transcription factor","volume":"44","author":"Liu","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2026092213562619000_bib17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.semcancer.2011.10.001","article-title":"Role of telomeres and telomerase in cancer","volume":"21","author":"Shay","year":"2011","journal-title":"Semin Cancer Biol"},{"key":"2026092213562619000_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1111","article-title":"Thyroid carcinoma-featured telomerase activation and telomere maintenance: biology and translational\/clinical significance","volume":"12","author":"Yuan","year":"2022","journal-title":"Clin Transl Med"},{"key":"2026092213562619000_bib19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3803\/EnM.2022.1477","article-title":"Frequency of TERT promoter mutations in real-world analysis of 2,092 thyroid carcinoma patients","volume":"37","author":"Yang","year":"2022","journal-title":"Endocrinol Metab"},{"key":"2026092213562619000_bib20","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.1002\/cam4.2467","article-title":"Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer","volume":"8","author":"Panebianco","year":"2019","journal-title":"Cancer Med"},{"key":"2026092213562619000_bib21","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Investig"},{"key":"2026092213562619000_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12020-019-02117-2","article-title":"Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis","volume":"67","author":"Yang","year":"2020","journal-title":"Endocrine"},{"key":"2026092213562619000_bib23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1530\/ERC-13-0210","article-title":"Highly prevalent TERT promoter mutations in aggressive thyroid cancers","volume":"20","author":"Liu","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"2026092213562619000_bib24","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0058","article-title":"Distinct transcriptional and prognostic impacts of TERT promoter mutations C228T and C250T in papillary thyroid carcinoma","volume":"31","author":"Marczyk","year":"2024","journal-title":"Endocr Relat Cancer"},{"key":"2026092213562619000_bib25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/cen.12845","article-title":"Comparison of differentiated thyroid cancer in children and adolescents (\u226420 years) with young adults","volume":"84","author":"Alzahrani","year":"2016","journal-title":"Clin Endocrinol"},{"key":"2026092213562619000_bib26","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1038\/s41588-025-02296-x","article-title":"Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis","volume":"57","author":"McLoughlin","year":"2025","journal-title":"Nat Genet"},{"key":"2026092213562619000_bib27","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1073\/pnas.1303607110","article-title":"TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal","volume":"110","author":"Killela","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026092213562619000_bib28","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1038\/s41467-022-33099-x","article-title":"Conserved features of TERT promoter duplications reveal an activation mechanism that mimics hotspot mutations in cancer","volume":"13","author":"Barger","year":"2022","journal-title":"Nat Commun"},{"key":"2026092213562619000_bib29","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1126\/science.aab0015","article-title":"The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer","volume":"348","author":"Bell","year":"2015","journal-title":"Science"},{"key":"2026092213562619000_bib30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/cancers14020357","article-title":"Multiple ETS factors participate in the transcriptional control of TERT mutant promoter in thyroid cancers","volume":"14","author":"Thornton","year":"2022","journal-title":"Cancers"},{"key":"2026092213562619000_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2020.07.003","article-title":"TERT promoter mutations and GABP transcription factors in carcinogenesis: more foes than friends","volume":"493","author":"Yuan","year":"2020","journal-title":"Cancer Lett"},{"key":"2026092213562619000_bib32","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1089\/thy.2018.0314","article-title":"ETS factor ETV5 activates the mutant telomerase reverse transcriptase promoter in thyroid cancer","volume":"29","author":"Bullock","year":"2019","journal-title":"Thyroid"},{"key":"2026092213562619000_bib33","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41467-018-03033-1","article-title":"Regulation of mutant TERT by BRAF V600E\/MAP kinase pathway through FOS\/GABP in human cancer","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"key":"2026092213562619000_bib34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41419-024-06454-7","article-title":"The regulations of telomerase reverse transcriptase (TERT) in cancer","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis"},{"key":"2026092213562619000_bib35","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1210\/clinem\/dgae589","article-title":"BRAF-induced EHF expression affects TERT in aggressive papillary thyroid cancer","volume":"110","author":"Xu","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092213562619000_bib36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/10507256261417697","article-title":"DDX21 links BRAFV600E and TERT to promote thyroid cancer progression","volume":"36","author":"Chen","year":"2026","journal-title":"Thyroid"},{"key":"2026092213562619000_bib37","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1158\/1541-7786.MCR-23-0144","article-title":"Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers nontelomeric effects","volume":"21","author":"Landa","year":"2023","journal-title":"Mol Cancer Res"},{"key":"2026092213562619000_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg7125","article-title":"TERT accelerates BRAF mutant\u2013induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis","volume":"9","author":"Yu","year":"2023","journal-title":"Sci Adv"},{"key":"2026092213562619000_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75087-9","article-title":"TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer","volume":"14","author":"Tan","year":"2024","journal-title":"Sci Rep"},{"key":"2026092213562619000_bib40","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/jnci\/djad265","article-title":"Genetic trio of BRAF and TERT alterations and rs2853669TT in papillary thyroid cancer aggressiveness","volume":"116","author":"Liu","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"2026092213562619000_bib41","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1089\/thy.2020.0055","article-title":"Characterization of allele-specific regulation of telomerase reverse transcriptase in promoter mutant thyroid cancer cell lines","volume":"30","author":"McKelvey","year":"2020","journal-title":"Thyroid"},{"key":"2026092213562619000_bib42","article-title":"TERT promoter methylation is associated with high expression of TERT and poor prognosis in papillary thyroid cancer","volume":"14","author":"Li","year":"2024","journal-title":"Front Oncol"},{"key":"2026092213562619000_bib43","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s12020-024-03722-6","article-title":"Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer","volume":"85","author":"Sang","year":"2024","journal-title":"Endocrine"},{"key":"2026092213562619000_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113194","article-title":"AURKB and PI3K\/AKT\/mTOR pathways converge to regulate TERT expression","volume":"28","author":"Lim","year":"2025","journal-title":"iScience"},{"key":"2026092213562619000_bib45","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.celrep.2015.05.015","article-title":"Aurora kinase B regulates telomerase activity via a centromeric RNA in stem cells","volume":"11","author":"Mallm","year":"2015","journal-title":"Cell Rep"},{"key":"2026092213562619000_bib46","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Agrawal","year":"2014","journal-title":"Cell"},{"key":"2026092213562619000_bib47","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.3390\/ijms26083663","article-title":"The revolution of targeted therapies in thyroid cancer treatment: present and future promising anti-cancer drugs","volume":"26","author":"Gil-Bernab\u00e9","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026092213562619000_bib48","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1038\/s41467-019-10680-5","article-title":"Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer","volume":"10","author":"Yoo","year":"2019","journal-title":"Nat Commun"},{"key":"2026092213562619000_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2024.105674","article-title":"Clinically aggressive follicular cell-derived thyroid carcinoma: a comprehensive series with histomolecular characterization and discovery of novel gene fusions","volume":"153","author":"Alsugair","year":"2024","journal-title":"Hum Pathol"},{"key":"2026092213562619000_bib50","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1101\/gad.251041.114","article-title":"Telomere position effect: regulation of gene expression with progressive telomere shortening over long distances","volume":"28","author":"Robin","year":"2014","journal-title":"Genes Dev"},{"key":"2026092213562619000_bib51","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1038\/ncomms6467","article-title":"TRF2 and lamin A\/C interact to facilitate the functional organization of chromosome ends","volume":"5","author":"Wood","year":"2014","journal-title":"Nat Commun"},{"key":"2026092213562619000_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1001","article-title":"Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markers","volume":"12","author":"Montero-Conde","year":"2022","journal-title":"Clin Transl Med"},{"key":"2026092213562619000_bib53","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/s41467-025-56947-y","article-title":"Genetic regulation of TERT splicing affects cancer risk by altering cellular longevity and replicative potential","volume":"16","author":"Florez-Vargas","year":"2025","journal-title":"Nat Commun"},{"key":"2026092213562619000_bib54","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1089\/thy.2008.0101","article-title":"Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms","volume":"18","author":"Wang","year":"2008","journal-title":"Thyroid"},{"key":"2026092213562619000_bib55","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ajpath.2011.05.056","article-title":"Telomere length is related to alternative splice patterns of telomerase in thyroid tumors","volume":"179","author":"Wang","year":"2011","journal-title":"Am J Pathol"},{"key":"2026092213562619000_bib56","doi-asserted-by":"crossref","first-page":"e1827","DOI":"10.1210\/clinem\/dgae220","article-title":"TERT promoter mutations increase tumor aggressiveness by altering TERT mRNA splicing in papillary thyroid carcinoma","volume":"109","author":"Sako","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092213562619000_bib57","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/ncb2621","article-title":"Telomerase directly regulates NF-\u03baB-dependent transcription","volume":"14","author":"Ghosh","year":"2012","journal-title":"Nat Cell Biol"},{"key":"2026092213562619000_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111464","article-title":"NF-\u03baB in thyroid cancer: an update","volume":"25","author":"Crescenzi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026092213562619000_bib59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41389-023-00496-w","article-title":"NF-\u03baB signaling activation and roles in thyroid cancers: implication of MAP3K14\/NIK","volume":"12","author":"Cormier","year":"2023","journal-title":"Oncogenesis"},{"key":"2026092213562619000_bib60","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/path.6351","article-title":"TERT upregulation promotes cell proliferation via degradation of p21 and increases carcinogenic potential","volume":"264","author":"Mishima","year":"2024","journal-title":"J Pathol"},{"key":"2026092213562619000_bib61","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0068","article-title":"Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer","volume":"31","author":"Seo","year":"2024","journal-title":"Endocr Relat Cancer"},{"key":"2026092213562619000_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1011923","article-title":"TERT translocation to mitochondria: exploring its role in mitochondrial homeostasis","volume":"21","author":"Marinaccio","year":"2025","journal-title":"PLoS Genet"},{"key":"2026092213562619000_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2024.04.004","article-title":"Extra-nuclear TERT counteracts oxidative stress and promotes progression in papillary thyroid carcinoma","volume":"271","author":"Muzza","year":"2024","journal-title":"Transl Res"},{"key":"2026092213562619000_bib64","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/dc.25120","article-title":"Digital droplet PCR TERT promoter mutational screening in fine needle aspiration cytology of thyroid lesions: a highly specific technique for pre-operative identification of high-risk cases","volume":"51","author":"Hysek","year":"2023","journal-title":"Diagn Cytopathol"},{"key":"2026092213562619000_bib65","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1177\/10507256251363450","article-title":"Pathological diagnosis of thyroid nodules with preoperatively detected TERT promoter mutations in the absence of BRAFV600E: A Bi-Center Series of 52 cases","volume":"35","author":"Alzumaili","year":"2025","journal-title":"Thyroid"},{"key":"2026092213562619000_bib66","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1158\/1078-0432.CCR-23-0278","article-title":"Additional oncogenic alterations in RAS -driven differentiated thyroid cancers associate with worse clinicopathologic outcomes","volume":"29","author":"Bikas","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026092213562619000_bib67","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1089\/thy.2015.0305","article-title":"Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with Atypia of undetermined significance\/follicular lesion of undetermined significance cytology","volume":"25","author":"Nikiforov","year":"2015","journal-title":"Thyroid"},{"key":"2026092213562619000_bib68","doi-asserted-by":"crossref","first-page":"E1852","DOI":"10.1210\/jc.2013-2292","article-title":"Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer","volume":"98","author":"Nikiforova","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092213562619000_bib69","doi-asserted-by":"crossref","first-page":"6965","DOI":"10.2147\/OTT.S116594","article-title":"Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis","volume":"9","author":"Su","year":"2016","journal-title":"Onco Targets Ther"},{"key":"2026092213562619000_bib70","doi-asserted-by":"crossref","first-page":"18346","DOI":"10.18632\/oncotarget.7811","article-title":"BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients","volume":"7","author":"Jin","year":"2016","journal-title":"Oncotarget"},{"key":"2026092213562619000_bib71","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1158\/1078-0432.CCR-22-2882","article-title":"Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy","volume":"29","author":"Boucai","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026092213562619000_bib72","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.119.227652","article-title":"The genetic duet of BRAFV600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer","volume":"61","author":"Liu","year":"2020","journal-title":"J Nucl Med"},{"key":"2026092213562619000_bib73","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2967\/jnumed.116.180240","article-title":"TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer","volume":"58","author":"Yang","year":"2017","journal-title":"J Nucl Med"},{"key":"2026092213562619000_bib74","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1210\/jc.2016-3434","article-title":"Refining dynamic risk stratification and prognostic groups for differentiated thyroid cancer with TERT promoter mutations","volume":"102","author":"Kim","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092213562619000_bib75","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41379-021-00907-6","article-title":"Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations","volume":"35","author":"Park","year":"2022","journal-title":"Mod Pathol"},{"key":"2026092213562619000_bib76","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/S1470-2045(25)00399-7","article-title":"Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study","volume":"26","author":"Xing","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026092213562619000_bib77","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1177\/10507256251370304","article-title":"Disease-specific and histological outcomes of preoperative TERT promoter mutation detected in isolation or in combination with other mutations in thyroid neoplasms","volume":"35","author":"Calcaterra","year":"2025","journal-title":"Thyroid"},{"key":"2026092213562619000_bib78","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejca.2018.08.013","article-title":"Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer","volume":"103","author":"Allin","year":"2018","journal-title":"Eur J Cancer"},{"key":"2026092213562619000_bib79","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.3390\/cancers13143443","article-title":"Translational utility of liquid biopsies in thyroid cancer management","volume":"13","author":"Wijewardene","year":"2021","journal-title":"Cancers"},{"key":"2026092213562619000_bib80","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1089\/thy.2020.0296","article-title":"Clinical utility of circulating cell-free DNA mutations in anaplastic thyroid carcinoma","volume":"31","author":"Qin","year":"2021","journal-title":"Thyroid"},{"key":"2026092213562619000_bib81","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3390\/healthcare9040386","article-title":"Limited clinical and diagnostic utility of circulating tumor DNA detection in patients with early-stage well-differentiated thyroid cancer: comparison with benign thyroid nodules and healthy individuals","volume":"9","author":"Suh","year":"2021","journal-title":"Healthcare"},{"key":"2026092213562619000_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102643","article-title":"Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: evidence from the Golestan Cohort Study","volume":"53","author":"Hosen","year":"2020","journal-title":"EBioMedicine"},{"key":"2026092213562619000_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75792-1","article-title":"Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients","volume":"10","author":"Marczynski","year":"2020","journal-title":"Sci Rep"},{"key":"2026092213562619000_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1720783","article-title":"Quantifying TERT promoter mutations in tumor-derived DNA shed into the oral cavity as a potential biomarker for oral squamous cell carcinoma","volume":"15","author":"Starita","year":"2025","journal-title":"Front Oncol"},{"key":"2026092213562619000_bib85","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1158\/0008-5472.CAN-13-2498","article-title":"TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine","volume":"73","author":"Kinde","year":"2013","journal-title":"Cancer Res"},{"key":"2026092213562619000_bib86","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1080\/00365521.2020.1837928","article-title":"TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma","volume":"55","author":"Oversoe","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"2026092213562619000_bib87","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70076","article-title":"Imetelstat, a novel, first-in-class telomerase inhibitor: mechanism of action, clinical, and translational science","volume":"17","author":"Lennox","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2026092213562619000_bib88","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1200\/JCO-25-01369","article-title":"US food and drug administration approval summary: imetelstat for selected patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia","volume":"43","author":"Kim","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026092213562619000_bib89","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s12032-023-02063-0","article-title":"Evaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycle","volume":"40","author":"Turkmen","year":"2023","journal-title":"Med Oncol"},{"key":"2026092213562619000_bib90","article-title":"Telomerase reverse transcriptase degradation via a rationally designed covalent proteolysis targeting chimera","volume":"125\u2013126","author":"Frost","year":"2025","journal-title":"Bioorg Med Chem Lett"},{"key":"2026092213562619000_bib91","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1158\/1078-0432.CCR-11-1385","article-title":"Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I\/II trial","volume":"17","author":"Brunsvig","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2026092213562619000_bib92","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1471-2407-10-209","article-title":"A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma","volume":"10","author":"Greten","year":"2010","journal-title":"BMC Cancer"},{"key":"2026092213562619000_bib93","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/sj.bjc.6603437","article-title":"Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I\/II study","volume":"95","author":"Bernhardt","year":"2006","journal-title":"Br J Cancer"},{"key":"2026092213562619000_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663865","article-title":"Combining a universal telomerase based cancer vaccine with ipilimumab in patients with metastatic melanoma \u2013 five-year follow up of a phase I\/IIa trial","volume":"12","author":"Aamdal","year":"2021","journal-title":"Front Immunol"},{"key":"2026092213562619000_bib95","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.ymthe.2020.11.019","article-title":"Targeting telomerase with an HLA class II-restricted TCR for cancer immunotherapy","volume":"29","author":"Dillard","year":"2021","journal-title":"Mol Ther"},{"key":"2026092213562619000_bib96","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.chembiol.2022.09.002","article-title":"Targeting telomerase reverse transcriptase with the covalent inhibitor NU-1 confers immunogenic radiation sensitization","volume":"29","author":"Liu","year":"2022","journal-title":"Cell Chem Biol"},{"key":"2026092213562619000_bib97","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.21037\/tcr-24-196","article-title":"Clinical research progress of telomerase targeted cancer immunotherapy: a literature review","volume":"13","author":"Wang","year":"2024","journal-title":"Transl Cancer Res"},{"key":"2026092213562619000_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1031232","article-title":"A phase I\/II escalation trial design T-RAD: treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)","volume":"12","author":"Maggad\u00f3ttir","year":"2022","journal-title":"Front Oncol"},{"key":"2026092213562619000_bib99","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.3390\/jcm13237021","article-title":"Redifferentiation therapies in thyroid oncology: molecular and clinical aspects","volume":"13","author":"Petranovi\u0107 Ov\u010dari\u010dek","year":"2024","journal-title":"J Clin Med"},{"key":"2026092213562619000_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1372553","article-title":"Advances in targeted therapy and biomarker research in thyroid cancer","volume":"15","author":"Guo","year":"2024","journal-title":"Front Endocrinol"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-26-0068\/525080\/etj-26-0068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-26-0068\/525080\/etj-26-0068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:56:47Z","timestamp":1790099807000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/15\/5\/ETJ260068\/78177\/TERT-reactivation-in-thyroid-cancer-mechanisms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-26-0068","relation":{},"ISSN":["2235-0802"],"issn-type":[{"value":"2235-0802","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"ETJ260068"}}